About the Authors
- Xiang Ling
-
Contributed equally to this work with: Xiang Ling, Shousong Cao
Affiliation Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America
- Shousong Cao
-
Contributed equally to this work with: Xiang Ling, Shousong Cao
Affiliations Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, United States of America
- Qiuying Cheng
-
Affiliation Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America
- James T. Keefe
-
Affiliation Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America
- Youcef M. Rustum
-
Affiliations Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America, NCI-supported Experimental Therapeutics Program, Roswell Park Cancer Institute, Buffalo, New York, United States of America
- Fengzhi Li
-
* E-mail: fengzhi.li@roswellpark.org
Affiliations Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America, NCI-supported Experimental Therapeutics Program, Roswell Park Cancer Institute, Buffalo, New York, United States of America
Competing Interests
FL118 will be further developed in Canget BioTekpharma (www.canget-biotek.com), a Roswell Park Cancer Institute (RPCI) spinoff company founded by the PI. Otherwise, there is no conflict of interest.
Author Contributions
Conceived and designed the experiments: XL SC YMR FL. Performed the experiments: XL SC QC JTK FL. Analyzed the data: XL SC. Contributed reagents/materials/analysis tools: SC YMR FL. Wrote the paper: FL. Read and revised the manuscript: XL SC QC JTK YMR FL.